TP

Takeda Pharmaceutical

October 2026

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study email from Takeda Pharmaceutical

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study

Captured October 23, 2026Announcement

Create this for my brand

FY2026 Q2 Results Webcast email from Takeda Pharmaceutical

FY2026 Q2 Results Webcast

Captured October 22, 2026Announcement

Create this for my brand

Shatoya’s psoriasis journey: More than a diagnosis email from Takeda Pharmaceutical

Shatoya’s psoriasis journey: More than a diagnosis

Captured October 21, 2026Newsletter

Create this for my brand

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication email from Takeda Pharmaceutical

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Captured October 19, 2026Announcement

Create this for my brand

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1 email from Takeda Pharmaceutical

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Captured October 15, 2026Announcement

Create this for my brand

Takeda to Hold Earnings Call for Fiscal Year 2026 2nd Quarter on October 29 email from Takeda Pharmaceutical

Takeda to Hold Earnings Call for Fiscal Year 2026 2nd Quarter on October 29

Captured October 15, 2026Announcement

Create this for my brand

Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026 email from Takeda Pharmaceutical

Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026

Captured October 14, 2026Announcement

Create this for my brand

September 2026

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill email from Takeda Pharmaceutical

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

Captured September 30, 2026Announcement

Create this for my brand

The doctor who sees narcolepsy through a patient’s eyes email from Takeda Pharmaceutical

The doctor who sees narcolepsy through a patient’s eyes

Captured September 29, 2026Newsletter

Create this for my brand

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026 email from Takeda Pharmaceutical

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

Captured September 22, 2026Announcement

Create this for my brand

Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems email from Takeda Pharmaceutical

Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems

Captured September 18, 2026Announcement

Create this for my brand

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations email from Takeda Pharmaceutical

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations

Captured September 14, 2026Announcement

Create this for my brand

Takeda Announces Planned Retirement of President of Research & Development Andy Plump email from Takeda Pharmaceutical

Takeda Announces Planned Retirement of President of Research & Development Andy Plump

Captured September 10, 2026Announcement

Create this for my brand

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life email from Takeda Pharmaceutical

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life

Captured September 9, 2026Announcement

Create this for my brand

August 2026

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera email from Takeda Pharmaceutical

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

Captured August 28, 2026Announcement

Create this for my brand

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 email from Takeda Pharmaceutical

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Captured August 24, 2026Announcement

Create this for my brand

Takeda’s Annual Integrated Report: Boldly reinventing for a healthier world email from Takeda Pharmaceutical

Takeda’s Annual Integrated Report: Boldly reinventing for a healthier world

Captured August 19, 2026Newsletter

Create this for my brand

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 email from Takeda Pharmaceutical

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Captured August 5, 2026Announcement

Create this for my brand

July 2026

Takeda FY2026 Q1 Earnings Summary email from Takeda Pharmaceutical

Takeda FY2026 Q1 Earnings Summary

Captured July 30, 2026Newsletter

Create this for my brand

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track email from Takeda Pharmaceutical

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track

Captured July 30, 2026Announcement

Create this for my brand

FY2026 Q1 Results Webcast email from Takeda Pharmaceutical

FY2026 Q1 Results Webcast

Captured July 23, 2026Announcement

Create this for my brand

Takeda’s ORZEYFUL (oveporexton) Approved in China as First Orexin Agonist and Only Medicine to Treat Narcolepsy Type 1 email from Takeda Pharmaceutical

Takeda’s ORZEYFUL (oveporexton) Approved in China as First Orexin Agonist and Only Medicine to Treat Narcolepsy Type 1

Captured July 23, 2026Announcement

Create this for my brand

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies email from Takeda Pharmaceutical

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

Captured July 16, 2026Announcement

Create this for my brand

Takeda to Hold Earnings Call for Fiscal Year 2026 1st Quarter on July 30 email from Takeda Pharmaceutical

Takeda to Hold Earnings Call for Fiscal Year 2026 1st Quarter on July 30

Captured July 16, 2026Announcement

Create this for my brand

Explore styles used by Takeda Pharmaceutical